Bruton’s tyrosine kinase inhibitors, such as ibrutinib, have transformed CLL treatment. At a conference, experts debated whether these medications can be stopped. One argued for discontinuation to avoid long-term toxicities and costs, while the other emphasized the effectiveness of continuous treatment for deepening responses and long remission times. Research is ongoing to determine the best approach. Audience members were divided on whether the drugs can be discontinued. Discontinuation may be necessary due to adverse events, but switching to a more tolerable inhibitor is an option. Further studies are needed to define the optimal regimen.
Source link
Should Patients With CLL Take Breaks From BTK Inhibitors?
